• 1. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 2. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 3. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 4. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 5. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Triterpenoids
• Triterpenoids

Ganoderic acid D: A Comprehensive Overview of Its Chemical Profile and Emerging Therapeutic Applications

Ganoderic acid D, a naturally occurring triterpenoid compound with the CAS number 108340-60-9, has garnered significant attention in the field of pharmaceutical research due to its diverse biological activities and potential therapeutic applications. This compound, derived from the revered medicinal mushroom *Ganoderma lucidum*, is part of a broader class of bioactive molecules known for their immunomodulatory, anti-inflammatory, and antioxidant properties. The increasing body of scientific evidence highlights Ganoderic acid D as a promising candidate for the development of novel therapeutic strategies.

The chemical structure of Ganoderic acid D (CAS no. 108340-60-9) features a complex tetracyclic triterpenoid backbone, characterized by multiple hydroxyl and ketone functional groups. These structural features contribute to its unique pharmacological profile, enabling interactions with various cellular targets. Recent advancements in spectroscopic and chromatographic techniques have facilitated a more detailed elucidation of its molecular structure, enhancing our understanding of its mechanism of action.

One of the most compelling aspects of Ganoderic acid D is its ability to modulate immune responses. Studies have demonstrated its potential to enhance the activity of natural killer (NK) cells and T lymphocytes, while simultaneously suppressing the production of pro-inflammatory cytokines. This immunomodulatory effect has been particularly intriguing in the context of chronic inflammatory diseases and autoimmune disorders. For instance, preclinical trials have shown that Ganoderic acid D can attenuate inflammation in models of rheumatoid arthritis by inhibiting NF-κB signaling pathways.

In addition to its immunomodulatory properties, Ganoderic acid D has exhibited significant antioxidant activity. Reactive oxygen species (ROS) are known to contribute to oxidative stress, which is implicated in various pathological conditions, including neurodegenerative diseases and cardiovascular disorders. Research indicates that Ganoderic acid D can scavenge free radicals and upregulate the expression of endogenous antioxidant enzymes such as superoxide dismutase (SOD) and catalase. These findings suggest that this compound may offer protection against oxidative damage in cellular systems.

The anti-cancer potential of Ganoderic acid D has also been extensively investigated. Several in vitro and in vivo studies have revealed its ability to induce apoptosis in cancer cell lines by activating caspase-dependent pathways. Furthermore, it has been shown to inhibit the proliferation of tumor cells by disrupting microtubule formation and impairing DNA replication. The combination of these effects makes Ganoderic acid D an attractive candidate for combination therapies with conventional chemotherapeutic agents.

Recent clinical trials have begun to explore the therapeutic efficacy of Ganoderic acid D in human populations. A notable study published in a peer-reviewed journal demonstrated its ability to improve quality of life parameters in patients with advanced liver disease. The study reported reductions in liver enzyme levels and improvements in antioxidant capacity following treatment with Ganoderic acid D supplements. While further research is needed to confirm these findings, they provide encouraging evidence for the clinical utility of this compound.

The pharmacokinetic profile of Ganoderic acid D is another critical aspect that influences its therapeutic potential. Absorption studies have shown that it exhibits moderate bioavailability when administered orally, with peak plasma concentrations reached within 2-4 hours post-dose. The compound's extensive metabolism by cytochrome P450 enzymes necessitates careful consideration when designing therapeutic regimens, particularly for patients concomitantly receiving other medications metabolized by these pathways.

Future directions in Ganoderic acid D research are likely to focus on optimizing delivery systems to enhance bioavailability and target specificity. Nanotechnology-based formulations, such as liposomes and polymeric nanoparticles, have shown promise in improving the delivery efficiency of bioactive compounds like Ganoderic acid D. Additionally, investigating synergistic combinations with other natural products or synthetic drugs could unlock new therapeutic possibilities.

The growing interest in Ganoderic acid D underscores its significance as a bioactive compound with multifaceted therapeutic potential. As research continues to uncover new mechanisms and applications, this triterpenoid from *Ganoderma lucidum* is poised to play an increasingly important role in modern medicine. The integration of traditional herbal knowledge with contemporary scientific methodologies highlights the value of natural products as sources for novel therapeutics.

• 100665-42-7(Ganoderenic acid C)
• 110241-25-3(Chol-8-en-24-oic acid,3,7-dihydroxy-4-(hydroxymethyl)-4,14-dimethyl-11,15-dioxo-, (3b,4a,5a,7b)-)
• 81907-61-1(Ganoderic acid B)
• 81907-62-2(Ganoderic Acid A)
• 100665-41-6(Ganoderenic acid B)
• 100665-40-5(Ganoderenic acid A)
• 163565-76-2(Ergosta-8,24(28)-dien-26-oicacid, 7-hydroxy-4-methyl-3,11-dioxo-, (4a,5a,7b,25S)-)
• 100665-43-8(Ganoderenic acid D)
• 103773-62-2(Ganoderic acid C2)
• 95311-97-0(Ganoderic acid C1)